For the latest COVID-19 Travel restrictions and recommendations please click here




In association with




Why you should attend:

Analyse development priorities
Discuss synergy strategies – what can be improved & what works well?
Hear ideas on how to improve COPD drug development
Explore how big Pharma can gain from co-operation with smaller pharmaceuticals companies
Join an interactive discussion session
Network with key industry professionals

Who should attend this event?

Industry professionals in positions such as:


  • Associate Clinician
  • Associate Director
  • Biomarker Specialist
  • Brand Manager
  • Business Development Director
  • CEO
  • Chief Executive Officer
  • Chief Medical Officer
  • Chief Scientific Officer
  • Clinical & Regulatory Strategy Manager
  • Clinical Pharmacologist
  • Clinical Trial Manager
  • Commercial Director
  • CSO
  • Director
  • Director of Medical Affairs
  • Head Global Licensing Respiratory
  • Head of Clinical Science
  • Head of Discovery
  • Head of Global Data Informatics - Global Preclinical R&D
  • Head of In-Vitro Biology
  • Head of Pharmacology
  • Head of Respiratory Pharmacology
  • Managing Director
  • Medical Affairs Director
  • Medical Director
  • Principal Scientist
  • Vice President
  • VP Chemistry
  • VP Inflammatory Disease Area
  • VP, Clinical Research Immunology
  • VP, Research





 What is this event about?

Asthma & COPD drug development of novel anti-inflammatory drugs is a problem for both big & small pharma companies. There are no predictive biomarkers for long term clinical benefit, limited knowledge on complex disease pathology and regulatory endpoints often do not reflect drug action. Challenges for small companies include the need for long clinical studies to demonstrate clinical benefit. Should small Pharma concentrate on early development including clinical Proof of Concept and what does this constitute for asthma and COPD? What kind of data package, including non-clinical safety, is expected by big Pharma for licensing etc ("selling package"). What are the key differences between clinically validated and non-validated targets? Expectations & needs of big Pharma differ: entry at what stage, portfolio aspects (e.g. combination therapy), devices ("should fit in existing device"). There is a clear need for early communication in order to learn about expectations. How can this process be synergized, all the way through from early joint development to trade selling?

This workshop will address these issues in an informal and progressive manner. Participants are encouraged to maximise the interactive nature of the workshop through participation and discussion.


Who is leading this event?

Daniel Bock, Chief Scientific Officer, Revotar 

Dr. Daniel Bock is Chief Scientific Officer of Revotar Biopharmaceuticals. He is Biologist with a continuous strong scientific interest in inflammation. Dr. Bock has more than 13 years experience in pharmaceutical research and development, covering a broad range from early drug discovery through to clinical proof of concept. He completed his PhD thesis at Medical School Hannover and subsequently was a Postdoctoral Scientist at Novartis Research Institute Vienna investigating inflammatory targets and mechanisms. At Revotar he previously held leading positions: Head of Biology, Director Preclinical R&D and Director Clinical Development.

Mary Fitzgerald, Executive VP Respiratory, Pulmagen

Mary Fitzgerald, PhD, is the Executive Vice President of Respiratory at Pulmagen Therapeutics, where she leads a multi-disciplinary team that specializes in pre-clinical safety, regulatory affairs, CMC and clinical operations. Dr Fitzgerald has been an Executive Director of Argenta/Pulmagen since 2004. She was also responsible for clinical development at Argenta from 2008 to 2010. Previously, Dr. Fitzgerald was with Bayer HealthCare for 14 years, latterly as Head of Pharmacology. She was also the Head of Pharmacology at Argenta for 6 years with responsibility for establishing disease relevant models of chronic respiratory disease.  She has spent over 20 years in the pharmaceutical industry and her major interest is in the development of anti-inflammatory therapies for COPD, asthma and cystic fibrosis.  She is currently involved in 4 inhaled anti-inflammatory programmes for COPD, including three programmes with the potential to switch on ICS in COPD and severe asthma.  She is also involved in the clinical development of an oral CRTh2 antagonist for asthma which is currently in Phase II.

Where does the event take place?

This Workshop will take place in central London, UK

Workshop programme

9:00 Registration & Coffee

9:30 Introduction by workshop leaders (scope of the workshop)

9:45 Drug development of anti-inflammatory drugs in Asthma & COPD: challenges for small pharmaceutical companies

10:15 Asthma & COPD drug development in big pharma: how to profit from small companies (options & expectations)

10:50 Coffee Break

11:20 How to synergize drug development of small and big pharma: general considerations, need for improvement, successful examples

12:00 Panel discussion

12:30 Close of Workshop


Copthorne Tara Hotel

Scarsdale Place
London W8 5SR
United Kingdom

Copthorne Tara Hotel

The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.




speaker image






CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.


There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.


Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.


Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title


Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event


Sign up
Forgotten Password?


UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71

Forgotten Password

Please enter the email address you registered with. We will email you a new password.

Thank you for visiting our event

If you would like to receive further information about our events, please fill out the information below.

By ticking above you are consenting to receive information by email from SMi.
Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out